8 employees
Immunis a private biotechnology company developing a novel treatment for age and disease-related immune decline.
2018
$10M
from 3 investors over 3 rounds
Immunis, Inc. raised $10M on August 3, 2022
Investors: Remiges Ventures, Inc. and Continuum Health Ventures
Immunis, Inc. raised undisclosed on January 1, 2020
Investors: Healthspan Capital